Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors ....
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.3 pts more than Nifty Microcap 250 and 6.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indoco Remedies reported audited results for FY2026. Standalone revenue grew 9.3% to Rs 1,63,354 lakhs, but the company posted a net loss of Rs 566 lakhs (improved from Rs 873 lakhs loss in FY2025). Consolidated revenue rose to Rs 1,79,294 lakhs, but consolidated net loss widened to Rs 9,870 lakhs due to significant losses in subsidiaries. Finance costs nearly doubled from Rs 5,663 to Rs 8,850 lakhs on standalone. The Board recommended a dividend of Rs 0.20 per share. Auditors issued unmodified opinions but included an Emphasis of Matter regarding FPP Holding LLC subsidiary, which has a negative net worth of Rs 8,225 lakhs and recurring losses, raising going concern doubts. Exceptional items of Rs 286 lakhs included trademark licensing income, loss on sale-leaseback, and Rs 419 lakhs impact from new labour codes.
The company continues to burn cash with large consolidated losses driven by subsidiary performance. Rising finance costs and a subsidiary with negative net worth create significant risk. The dividend recommendation is modest and subject to shareholder approval. Investors should monitor the FPP Holding LLC situation closely as auditors flagged material uncertainty about its ability to continue as a going concern.